• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML.

作者信息

Jia Yannan, Zhang Weiguo, Basyal Mahesh, Chang Kyung Hee, Ostermann Lauren, Burks Jared K, Ly Charlie, Mu-Mosley Hong, Zhang Qi, Han Xin, Fogler William E, Magnani John L, Lesegretain Arnaud, Zal Anna A, Zal Tomasz, Andreeff Michael

机构信息

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.

出版信息

Leukemia. 2023 Jun;37(6):1379-1383. doi: 10.1038/s41375-023-01897-x. Epub 2023 Apr 21.

DOI:10.1038/s41375-023-01897-x
PMID:37085610
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10244167/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3367/10244167/19838c252bfe/41375_2023_1897_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3367/10244167/4b5eaf564f6b/41375_2023_1897_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3367/10244167/19838c252bfe/41375_2023_1897_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3367/10244167/4b5eaf564f6b/41375_2023_1897_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3367/10244167/19838c252bfe/41375_2023_1897_Fig2_HTML.jpg

相似文献

1
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML.FLT3抑制剂通过抑制AML细胞中的ERK上调CXCR4和E-选择素配体，而CXCR4/E-选择素抑制增强了FLT3靶向治疗AML的抗白血病疗效。
Leukemia. 2023 Jun;37(6):1379-1383. doi: 10.1038/s41375-023-01897-x. Epub 2023 Apr 21.
2
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.通过抑制CXCR4靶向白血病微环境可克服急性髓系白血病对激酶抑制剂和化疗的耐药性。
Blood. 2009 Jun 11;113(24):6215-24. doi: 10.1182/blood-2008-05-158311. Epub 2008 Oct 27.
3
The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.双重MEK/FLT3抑制剂E6201对携带赋予耐药性的FLT3突变的急性髓系白血病细胞具有细胞毒活性。
Cancer Res. 2016 Mar 15;76(6):1528-37. doi: 10.1158/0008-5472.CAN-15-1580. Epub 2016 Jan 28.
4
The magnitude of CXCR4 signaling regulates resistance to quizartinib in FLT3/ITD cells via RUNX1.CXCR4信号的强度通过RUNX1调节FLT3/ITD细胞对奎扎替尼的耐药性。
Leuk Res. 2023 Jan;124:106983. doi: 10.1016/j.leukres.2022.106983. Epub 2022 Oct 29.
5
The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia.FLT3-ITD 突变及其下游信号转导介质 STAT5 和 Pim-1 的表达与急性髓系白血病患者的 CXCR4 表达呈正相关。
Sci Rep. 2019 Aug 21;9(1):12209. doi: 10.1038/s41598-019-48687-z.
6
Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.Mer和Flt3酪氨酸激酶小分子抑制剂UNC1666在急性髓系白血病中的疗效
Oncotarget. 2015 Mar 30;6(9):6722-36. doi: 10.18632/oncotarget.3156.
7
ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.ULK1 抑制作为 FLT3-ITD 突变型急性髓系白血病的靶向治疗策略。
J Exp Clin Cancer Res. 2020 May 11;39(1):85. doi: 10.1186/s13046-020-01580-4.
8
Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.通过不同的联合用药策略逆转FLT3突变的急性髓系白血病细胞中的获得性耐药
Clin Cancer Res. 2014 May 1;20(9):2363-74. doi: 10.1158/1078-0432.CCR-13-2052. Epub 2014 Mar 11.
9
Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD acute myeloid leukemia.联合抑制 Notch 和 FLT3 在 FLT3/ITD 急性髓系白血病中产生协同细胞毒性作用。
Signal Transduct Target Ther. 2020 Mar 13;5(1):21. doi: 10.1038/s41392-020-0108-z.
10
FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.FLT3 抑制通过 FOXO 上调 HDAC8，使 p53 失活，从而促进 FLT3-ITD+ 急性髓系白血病的维持。
Blood. 2020 Apr 23;135(17):1472-1483. doi: 10.1182/blood.2019003538.

引用本文的文献

1
Restricted human CD45 isoglycoforms serve as functional E-selectin ligands and delineate hematopoietic maturity.受限的人类CD45同工型作为功能性E-选择素配体并描绘造血成熟度。
J Biol Chem. 2025 Jul 1;301(8):110431. doi: 10.1016/j.jbc.2025.110431.
2
Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias.喹扎替尼和米拉德美坦联合抑制FLT3-ITD和MDM2在FLT3-ITD突变/TP53野生型急性髓系白血病中的协同活性
Clin Cancer Res. 2025 Jul 15;31(14):3033-3047. doi: 10.1158/1078-0432.CCR-24-2764.
3
Small Extracellular Vesicles from Breast Cancer Cells Induce Cardiotoxicity.

本文引用的文献

1
The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities.缺氧骨髓微环境在急性髓系白血病中的作用及未来治疗机会。
Int J Mol Sci. 2021 Jun 25;22(13):6857. doi: 10.3390/ijms22136857.
2
Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies.急性髓系白血病中的突变：关键概念与新出现的争议
Front Oncol. 2020 Dec 23;10:612880. doi: 10.3389/fonc.2020.612880. eCollection 2020.
3
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
乳腺癌细胞来源的小细胞外囊泡可诱导心脏毒性。
Int J Mol Sci. 2025 Jan 23;26(3):945. doi: 10.3390/ijms26030945.
4
Endothelial heterogeneity in bone marrow: insights across development, adult life and leukemia.骨髓中的内皮异质性：发育、成年期及白血病中的见解
Leukemia. 2025 Jan;39(1):8-24. doi: 10.1038/s41375-024-02453-x. Epub 2024 Nov 11.
5
Overexpression of Nrf2 in bone marrow mesenchymal stem cells promotes B-cell acute lymphoblastic leukemia cells invasion and extramedullary organ infiltration through stimulation of the SDF-1/CXCR4 axis.骨髓间充质干细胞中Nrf2的过表达通过刺激SDF-1/CXCR4轴促进B细胞急性淋巴细胞白血病细胞的侵袭和髓外器官浸润。
Front Pharmacol. 2024 Jul 16;15:1393482. doi: 10.3389/fphar.2024.1393482. eCollection 2024.
6
Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?通过抑制 E-选择素来靶向血液系统恶性肿瘤：AML 治疗的新靶点？
Blood Rev. 2024 May;65:101184. doi: 10.1016/j.blre.2024.101184. Epub 2024 Feb 28.
7
The Rac1-inhibitor EHop-016 attenuates AML cell migration and enhances the efficacy of daunorubicin in MOLM-13 transplanted zebrafish larvae.Rac1抑制剂EHop-016可减弱急性髓系白血病（AML）细胞的迁移能力，并增强柔红霉素对移植了MOLM-13细胞的斑马鱼幼体的疗效。
Transl Oncol. 2024 Feb;40:101876. doi: 10.1016/j.tranon.2024.101876. Epub 2024 Jan 6.
8
The interplay of FLT3 and CXCR4 in acute myeloid leukemia: an ongoing debate.FLT3与CXCR4在急性髓系白血病中的相互作用：一场仍在进行的争论。
Front Oncol. 2023 Oct 2;13:1258679. doi: 10.3389/fonc.2023.1258679. eCollection 2023.
9
Uncovering NOTCH1 as a Promising Target in the Treatment of -Rearranged Leukemia.揭示 NOTCH1 作为治疗 - 重排白血病的有希望的靶点。
Int J Mol Sci. 2023 Sep 23;24(19):14466. doi: 10.3390/ijms241914466.
BL-8040 CXCR4 拮抗剂联合阿糖胞苷治疗复发/难治性急性髓系白血病的安全性和疗效的开放标签 2a 期研究：安全且具有抗白血病活性。
Cancer. 2021 Apr 15;127(8):1246-1259. doi: 10.1002/cncr.33338. Epub 2020 Dec 3.
4
Cytokine control of megakaryopoiesis.细胞因子对巨核细胞生成的调控
Growth Factors. 2018 Aug;36(3-4):89-103. doi: 10.1080/08977194.2018.1498487. Epub 2018 Oct 15.
5
Role of Microenvironment in Resistance to Therapy in AML.微环境在急性髓系白血病治疗耐药中的作用
Curr Hematol Malig Rep. 2015 Jun;10(2):96-103. doi: 10.1007/s11899-015-0253-6.
6
Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy.克服针对FLT3的急性髓系白血病治疗中因合成致死毒性导致的骨髓抑制。
Elife. 2014 Dec 22;3:e03445. doi: 10.7554/eLife.03445.
7
Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance.血管生态位 E-选择素调控造血干细胞休眠、自我更新和化疗耐药性。
Nat Med. 2012 Nov;18(11):1651-7. doi: 10.1038/nm.2969. Epub 2012 Oct 21.
8
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.突变型FLT3：急性髓性白血病中索拉非尼的直接作用靶点。
J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328. Epub 2008 Jan 29.
9
CXCR4 is a prognostic marker in acute myelogenous leukemia.CXCR4是急性髓系白血病的一个预后标志物。
Blood. 2007 Jan 15;109(2):786-91. doi: 10.1182/blood-2006-05-024844. Epub 2006 Aug 3.
10
How do stem cells find their way home?干细胞是如何找到它们的归巢之路的？
Blood. 2005 Sep 15;106(6):1901-10. doi: 10.1182/blood-2005-04-1417. Epub 2005 May 12.